bioRxivCancer BiologyPreprint
ULK1 drives NDP52-mediated selective autophagic degradation of MHC-I to promote immune evasion in HPV-positive head and neck cancer
Lexi VuiD, Nicholas S. GiacobbiiD, M. I. KhaliliD, Canchai YangiD, Will EckermaniD, Evelyn Gomez RecinosiD, Johnathon D. GarberiD, Hyomin SoniD, Prerna ChahaliD, Dara M VillaiD, Tasha Srivastava, Abigail Z. BennettiD, Katie R. MartiniD, Craig C. WelboniD, Caitlin S. WilliamsoniD, William Charles SpanosiD, Jeffrey P. MacKeiganiD, Andrew J. OliveiD, Dohun PyeoniD
Abstract
Antigen presentation by major histocompatibility complex class I (MHC-I) is critical for tumor cell killing by CD8+ T cells. Accordingly, tumor cells downregulate MHC-I expression through multiple mechanisms, thereby evading the immune response. Importantly, lower levels of MHC-I are associated with poor responses to immune checkpoint inhibitor therapy. Our recent study has shown that the human papillomavirus (HPV) oncoproteins induce MHC-I protein ubiquitination by membrane-associated Ring-CH-type finger 8 (MARCHF8) in HPV-positive head and neck cancer (HPV+ HNC). However, the mechanism by which ubiquitinated MHC-I is degraded remains elusive. By performing genome-wide CRISPR screens, we identified components of the ULK1 and PIK3C3 complexes for autophagy initiation complexes among the top negative regulators of cell-surface MHC-I expression in HPV+ HNC cells. We show that MHC-I is recruited from the ER to autophagosomes by the cargo receptor NDP52, decreasing MHC-I levels. Further, inhibiting the initiation or nucleation steps of autophagy before autophagosome formation is critical for restoring MHC-I levels on the cell surface. Finally, genetic inhibition of autophagy initiation suppresses HPV+ HNC tumor growth in vivo and enhances the CD8+ T cell-mediated antitumor response. Our findings suggest that autophagic degradation of MARCHF8-ubiquitinated MHC-I is a key immune evasion mechanism in HPV+ HNC.
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: host-pathogen & immune response
- approach: genetic perturbation / CRISPR
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The membrane-associated ubiquitin ligase MARCHF8 promotes cancer immune evasion by degrading MHC class I proteins
M. I. Khalil, Jie Wang, … Dohun Pyeon·Proceedings of the National Academy of SciencesPeer-reviewed·Mar 9, 2026
- HPV E6 upregulates MARCHF8 ubiquitin ligase and inhibits apoptosis by degrading the death receptors in head and neck cancer
M. I. Khalil, C. Yang, … D. Pyeon·bioRxiv·Sep 7, 2022
- MAPK ERK5 Is a Novel Regulator of MHC-I in Cancer Cells
Maria Viñas-Casas, José Miguel Lizcano·Cell Communication and SignalingPeer-reviewed·Mar 9, 2026
- A multi-subunit autophagic capture complex facilitates degradation of ER stalled MHC-I in pancreatic cancer.
Marine Berquez, Alexander L. Li, … Rushika M. Perera·Molecular CellPeer-reviewed·May 29, 2026
- The membrane-associated ubiquitin ligase MARCHF8 stabilizes the human papillomavirus oncoprotein E7 by degrading CUL1 and UBE2L3 in head and neck cancer
M. I. Khalil, C. Yang, … D. Pyeon·bioRxiv·Nov 3, 2023
- Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer
Tracess B. Smalley, Angelo A. Nicolaci, … Jennifer M. Binning·Molecular TherapyPeer-reviewed·Aug 26, 2025